CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 10
Summary
- Conditions
- Leukemia Myeloid Acute
- Leukemia, Relapsed Adult Acute Myeloid
- Myelodysplastic Syndromes
- Myelodysplastic Syndromes, Previously Treated
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 89 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03393611
- Collaborators
- Jazz Pharmaceuticals
- Investigators
- Principal Investigator: Koen van Besien, MD, PhD Weill Medical College of Cornell University
Get Well Soon